REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Real-time Estimate Cboe BZX  -  12:03 2022-08-17 pm EDT
641.07 USD   -1.18%
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/09INSIDER SELL : Regeneron Pharmaceuticals
MT
08/04Goldman Sachs Increases Regeneron Pharmaceuticals' Price Target to $796 From $790, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 41 04950 99066 02969 351--
Enterprise Value (EV)1 35 29150 09856 19664 51256 77257 963
P/E ratio 20,3x15,8x8,77x18,9x16,9x15,7x
Yield ------
Capitalization / Revenue 5,22x6,00x4,11x5,88x5,56x5,38x
EV / Revenue 4,49x5,90x3,50x5,47x4,55x4,49x
EV / EBITDA 10,3x11,8x5,71x10,7x8,93x8,73x
Price to Book 3,70x4,71x3,56x2,74x2,33x2,00x
Nbr of stocks (in thousands) 109 323105 544104 556106 908--
Reference price (USD) 375483632649649649
Announcement Date 02/06/202002/05/202102/04/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 7 8638 49716 07211 79812 48212 901
EBITDA1 3 4204 2459 8356 0116 3606 640
Operating profit (EBIT)1 2 2103 5778 9475 4695 7495 908
Operating Margin 28,1%42,1%55,7%46,4%46,1%45,8%
Pre-Tax Profit (EBT)1 2 4293 8109 3264 6624 9075 387
Net income1 2 1163 5138 0753 8074 0314 164
Net margin 26,9%41,3%50,2%32,3%32,3%32,3%
EPS2 18,530,572,034,438,341,3
Dividend per Share2 ------
Announcement Date 02/06/202002/05/202102/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1
Net sales1 4 9522 9652 8572 8603 0842 950
EBITDA1 2 9031 5581 3441 408994-
Operating profit (EBIT)1 2 6401 4831 2701 2921 2851 351
Operating Margin 53,3%50,0%44,4%45,2%41,7%45,8%
Pre-Tax Profit (EBT)1 2 5031 0619631 1541 1591 468
Net income1 2 229974852880931947
Net margin 45,0%32,8%29,8%30,8%30,2%32,1%
EPS2 19,78,617,478,609,368,42
Dividend per Share ------
Announcement Date 02/04/202205/04/202208/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 5 7578919 8334 83912 58011 389
Leverage (Debt / EBITDA) -1,68x-0,21x-1,00x-0,81x-1,98x-1,72x
Free Cash Flow1 2 0002 0046 5296 3264 9785 132
ROE (Net Profit / Equities) 28,5%33,2%54,2%21,3%18,6%16,8%
Shareholders' equity1 7 42710 59514 89717 87621 68624 815
ROA (Net Profit / Asset) 15,9%22,0%37,9%13,7%14,5%14,4%
Assets1 13 27015 98421 29927 78727 81828 981
Book Value Per Share2 102102178237279325
Cash Flow per Share2 21,222,763,166,342,251,2
Capex1 430615552602617618
Capex / Sales 5,46%7,23%3,43%5,10%4,94%4,79%
Announcement Date 02/06/202002/05/202102/04/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 69 351 428 481
Net sales (USD) 16 071 700 000
Number of employees 10 715
Sales / Employee (USD) 1 499 925
Free-Float 80,5%
Free-Float capitalization (USD) 55 800 818 644
Avg. Exchange 20 sessions (USD) 414 341 978
Average Daily Capital Traded 0,60%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA